For Research Purposes Only — This article discusses PT-141 (Bremelanotide) as a laboratory research compound and summarizes published preclinical and clinical literature for research reference. The content is intended strictly for researchers, scientists, and educators. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. Nothing in this article should be interpreted as medical advice or as a recommendation to use bremelanotide, Vyleesi, or any related compound outside of a properly regulated clinical or research setting.
Introduction
PT-141, known in the clinical literature as bremelanotide and marketed in the United States under the brand name Vyleesi, is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) with high affinity for the melanocortin system. It is one of the most mechanistically interesting peptides in modern neuropharmacology: unlike peripheral peptides that act on circulating or tissue-local receptors, PT-141 exerts its principal effects on centrally located melanocortin receptors, particularly the melanocortin-4 receptor (MC4R) in the hypothalamus and limbic circuits.
The research history of PT-141 is a useful case study in the unexpected directions peptide pharmacology can take. The parent compound, melanotan-II, was originally developed by Palatin Technologies and collaborators as a skin-tanning agent through melanocortin-1 receptor (MC1R) agonism. Early clinical observations, however, revealed that some subjects experienced effects on sexual arousal that could not be attributed to MC1R. Medicinal chemistry campaigns aimed at stripping away the tanning activity while preserving the central melanocortin effect yielded PT-141 — a structurally distinct analog with a very different receptor selectivity profile and a focus on central MC3R/MC4R pathways.
This research monograph consolidates what the published literature reports about PT-141’s structure, its receptor pharmacology, its behavior in preclinical models, and the context of its US FDA approval in 2019 as bremelanotide (Vyleesi) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Every claim is tied to a cited source. The approved clinical context is discussed here for reference only — this article makes no claims about how PT-141 should be used outside of regulated clinical or laboratory research settings.
Molecular Structure and Biochemistry
Bremelanotide is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The cyclization is achieved via a lactam bridge between the side chains of the aspartate and lysine residues, conferring conformational rigidity to the “message sequence” at the heart of the molecule. The molecular weight is approximately 1,025 Da. N-terminal acetylation and the use of unnatural amino acids (Nle for norleucine in place of methionine, D-Phe for D-phenylalanine) are standard medicinal-chemistry modifications that improve metabolic stability and optimize receptor binding.
The core “His-D-Phe-Arg-Trp” motif is the canonical melanocortin message sequence found in α-MSH, β-MSH, and γ-MSH. In linear α-MSH this sequence is conformationally flexible; cyclization locks it into a bioactive conformation that binds the melanocortin receptor family with substantially higher potency than the linear parent. Bremelanotide retains this message sequence in a cyclic scaffold optimized for MC4R engagement.
Importantly, bremelanotide is the des-amide, non-tanning analog of its closely related predecessor, melanotan-II. The removal of the C-terminal amide, along with the replacement of specific residues, shifts receptor selectivity away from MC1R (skin pigmentation) and toward MC3R/MC4R (central nervous system) — although bremelanotide still retains measurable activity at multiple melanocortin receptor subtypes.
The peptide is a white-to-off-white lyophilized powder in its research-grade form. It is highly water-soluble and is typically reconstituted in sterile water or saline for experimental use. Subcutaneous administration provides rapid absorption; the approved formulation in humans achieves peak plasma concentrations within approximately 1 hour, with an elimination half-life of roughly 2.7 hours. These pharmacokinetic parameters are well-characterized because bremelanotide went through formal Phase 1, 2, and 3 clinical development as summarized by Dhillon and Keam (DOI).
Mechanism of Action in Research Models
The melanocortin receptor family
The melanocortin system consists of five G-protein-coupled receptors (MC1R–MC5R), all of which couple primarily to Gαs and elevate intracellular cAMP upon activation. Their endogenous ligands are derived from proopiomelanocortin (POMC) processing and include α-MSH, β-MSH, γ-MSH, and ACTH. The receptors are functionally specialized:
- MC1R is expressed on melanocytes and regulates eumelanin synthesis — this is the receptor targeted by tanning agents like melanotan-II and afamelanotide.
- MC2R is the ACTH receptor in the adrenal cortex, regulating glucocorticoid production.
- MC3R and MC4R are expressed predominantly in the central nervous system, with MC4R being particularly important for energy homeostasis, feeding behavior, and — as has become clear over the last two decades — sexual response circuits.
- MC5R is widely distributed and has less well-defined functions.
Sweeney and colleagues, in a 2023 Nature Reviews Endocrinology review of the central melanocortin system, summarized the critical role of MC4R-containing circuits in the regulation of metabolism, feeding, and behavior, and described how the system has become an increasingly productive therapeutic target — a conclusion reinforced by the FDA approvals of setmelanotide for certain forms of syndromic obesity, bremelanotide for generalized HSDD, and afamelanotide for erythropoietic protoporphyria (DOI).
Bremelanotide and MC4R
Bremelanotide is characterized in the pharmacology literature as a non-selective melanocortin receptor agonist with meaningful activity at MC1R, MC3R, MC4R, and MC5R, but with its clinically relevant effects attributed to MC4R activation in central nervous system circuits. Dhillon and Keam described bremelanotide as a synthetic peptide analogue of α-MSH with high affinity for MC4R, “thought to be important for sexual function,” giving it the potential to modulate brain pathways involved in sexual response (DOI).
At the circuit level, MC4R-expressing neurons in the paraventricular nucleus of the hypothalamus, the medial preoptic area, and other limbic structures are positioned to influence sexual motivation and arousal. Preclinical work in rodent models has implicated these circuits in proceptive behaviors in females and erectile function in males, and MC4R activation in these regions has been reported to modulate both. This mechanism is distinct from peripheral vasodilator approaches (e.g., PDE5 inhibitors), which act on the vascular response rather than on the central motivational component.
Feeding, energy homeostasis, and metabolic effects
Because MC4R is a master regulator of energy balance, melanocortin agonists generally have effects on feeding and body weight. Setmelanotide — a different, more selective MC4R agonist — is FDA-approved for weight management in specific forms of syndromic obesity. Bremelanotide’s acute dosing regimen and receptor promiscuity mean that weight-regulatory effects are not its primary clinical profile, but the Sweeney review places bremelanotide within the broader central melanocortin pharmacology context (DOI).
Cardiovascular and pigmentation effects
MC1R activation can cause transient skin darkening (the original “tanning” phenotype of melanotan-II); bremelanotide retains some MC1R activity and focal hyperpigmentation has been reported in clinical trials. MC4R activation can transiently increase blood pressure via central sympathetic outflow; clinical safety data for bremelanotide include a small, transient post-dose increase in systolic blood pressure, which is documented in the approved prescribing information for Vyleesi and discussed in clinical reviews.
These peripheral effects are important for preclinical researchers to consider when interpreting behavioral readouts in rodent experiments — for example, acute blood pressure or locomotor changes may confound motivational assays.
Key Research Areas
Preclinical sexual behavior models
The foundational preclinical work establishing melanocortin involvement in sexual response predates PT-141’s clinical development by decades. Rodent studies have consistently demonstrated that central MC4R activation influences copulatory behavior in male rats and proceptive behavior in female rats. Hedlund’s 2004 review of the PT-141 program summarized the preclinical rationale and the early clinical data, noting that the peptide was being developed as a nasal spray at that time for erectile dysfunction and female sexual dysfunction ([DOI unavailable, PMID 15134289]). The nasal-spray development path was later abandoned, and the subcutaneous formulation became the basis for the subsequent Vyleesi product.
Clinical development in hypoactive sexual desire disorder
The pivotal Phase 3 program for bremelanotide enrolled premenopausal women with acquired, generalized HSDD — defined by the DSM-5 and ICD frameworks as a persistent deficiency or absence of sexual fantasies and desire that causes personal distress and is not attributable to another medical condition or a relationship problem. Edinoff and colleagues reviewed the bremelanotide development program and reported that studies showed improvements in desire, arousal, and orgasm scores when 1.75 mg bremelanotide was administered subcutaneously before sexual activity, compared to placebo (DOI). The FDA approved bremelanotide (Vyleesi) in June 2019 on the basis of two placebo-controlled Phase 3 trials.
Dhillon and Keam’s Drugs profile on the first approval of bremelanotide summarized the complete development history: initial development by Palatin Technologies with subsequent out-licensing to AMAG Pharmaceuticals, the Phase 3 clinical program, and the final regulatory outcome (DOI).
HSDD physiology and the dual control model
Pettigrew and Novick, in a 2021 clinical overview of HSDD for the midwifery and women’s health community, described the condition as characterized by a deficiency of sexual thoughts, feelings, or receptiveness that has been present for at least six months, causes personal distress, and is not due to another medical condition. They reviewed the biopsychosocial framework underlying HSDD and discussed the two FDA-approved medications — flibanserin and bremelanotide — as well as off-label options. Their review emphasized that HSDD is common, likely underrecognized, and that clinical assessment requires a careful biopsychosocial approach (DOI).
This physiological framing is useful for preclinical researchers because it ties rodent assays of sexual motivation (which are fundamentally behavioral) to a clinically defined human phenotype that depends on both central nervous system and psychosocial factors.
Broader melanocortin therapeutic landscape
The Sweeney et al. review places bremelanotide in a broader context of melanocortin system drug development. The authors noted that FDA approvals of setmelanotide for syndromic obesity, bremelanotide for HSDD, and afamelanotide for erythropoietic protoporphyria-associated phototoxicity have renewed interest in melanocortin-targeted therapeutics for a range of metabolic and behavioral disorders. They argued that the safety profile established by these three drugs has made it more tractable to develop next-generation melanocortin ligands (DOI).
Neurological research beyond sexual behavior
Because MC4R-expressing neurons are distributed throughout the brain and have been implicated in feeding, cognition, anxiety, and pain modulation, the melanocortin system is an active area of preclinical research beyond the sexual behavior domain. Bremelanotide, as a non-selective agonist with demonstrated CNS penetration and established safety in humans, is sometimes used as a research tool compound to probe central melanocortin pharmacology in rodents and in in vitro neural tissue preparations.
Stability, Storage, and Handling in the Laboratory
Research-grade PT-141 / bremelanotide is supplied as a lyophilized white powder. Stored at -20 °C or -80 °C in its lyophilized state, protected from light and moisture, the peptide is reported to be stable for extended periods. Brief exposure to ambient temperatures during shipping is generally tolerated.
Reconstitution is typically performed in sterile bacteriostatic water or sterile water for injection. Because the peptide is cyclic and contains unnatural amino acids, it is more metabolically stable than most linear peptides, but post-reconstitution storage still benefits from refrigeration and protection from freeze-thaw cycles. Aliquoting into single-use vials is standard practice for any quantitative assay.
Working concentrations for research are experiment-dependent. Rodent behavioral studies typically use subcutaneous dosing at milligram-per-kilogram ranges; in vitro receptor pharmacology studies use nanomolar to micromolar concentrations. The specific activity of any given lot should be confirmed against the Certificate of Analysis.
Researchers using PT-141 in behavioral assays should be aware of two practical confounders. First, cyclic peptides can be challenging to dissolve fully if the buffer pH or ionic strength is mismatched; gentle warming and extended equilibration may be needed. Second, bremelanotide causes transient pigmentation changes and mild cardiovascular effects in some animal models — these should be either controlled for or used as positive pharmacological markers of receptor engagement.
This handling guidance is for laboratory research use only. PT-141 / bremelanotide should only be administered to humans in properly regulated clinical settings with an approved indication.
Research Considerations and Limitations
First, the translational story of PT-141 is instructive but narrow. The approved indication (generalized HSDD in premenopausal women) reflects the specific patient population in which Phase 3 trials were conducted. Extrapolating the clinical data to other populations, indications, or dosing regimens is not supported by the regulatory dossier and is outside the scope of research-use-only discussion.
Second, bremelanotide is a non-selective melanocortin agonist. Its clinical effects cannot be cleanly attributed to a single receptor subtype, and preclinical work using bremelanotide as a “MC4R tool compound” should be interpreted with caution — selective MC4R agonists like setmelanotide may be more appropriate for receptor-specific mechanistic questions.
Third, the peptide has meaningful safety considerations even in its approved clinical context: transient blood pressure elevation, focal hyperpigmentation, nausea, and injection-site reactions are all documented. Edinoff and colleagues summarized the clinical safety profile, noting that the recommended clinical dose is 1.75 mg administered subcutaneously at least 45 minutes before sexual activity (DOI). These details are provided here for reference only and do not constitute dosing guidance.
Fourth, the research literature on non-sexual CNS applications of bremelanotide is still relatively thin. While the peptide has theoretical relevance for feeding, mood, and pain research via the central melanocortin system, translational confirmation is limited.
Fifth, as with all approved prescription drugs, use of bremelanotide outside of a regulated clinical context raises serious safety, ethical, and legal concerns. This article makes no claims and provides no guidance about such use.
Frequently Asked Research Questions
Q: Is PT-141 the same molecule as bremelanotide / Vyleesi?
A: Yes. PT-141 is the laboratory/development code, bremelanotide is the generic drug name, and Vyleesi is the US brand name for the commercial product approved in 2019. All three refer to the same cyclic heptapeptide (DOI).
Q: How is PT-141 related to melanotan-II?
A: PT-141 is a structurally distinct analog derived from the melanotan-II pharmacology program. Melanotan-II retains strong MC1R agonism (pigmentation) while PT-141 has been engineered to shift activity toward MC3R/MC4R with reduced tanning effect, though some MC1R activity remains.
Q: What is the primary receptor mechanism?
A: Bremelanotide activates multiple melanocortin receptors, but its clinically relevant effects are thought to be mediated by MC4R activation in central nervous system circuits, particularly in hypothalamic and limbic regions involved in sexual motivation and arousal (DOI, DOI).
Q: What was the FDA approval basis for Vyleesi?
A: Bremelanotide was approved in June 2019 for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder based on two placebo-controlled Phase 3 trials. The approved dose is 1.75 mg subcutaneously, administered on-demand at least 45 minutes before anticipated sexual activity (DOI).
Q: Can PT-141 be used as a tool compound for central melanocortin research?
A: Yes, with appropriate caveats. PT-141 is a useful reagent for probing central melanocortin biology in rodents and in vitro, but researchers should recognize its non-selective receptor profile and consider pairing it with selective MC4R agonists or antagonists to establish receptor-specific mechanisms.
References
- Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79(14):1599-1606. PMID: 31429064. DOI
- Hedlund P. PT-141 Palatin. Curr Opin Investig Drugs. 2004;5(4):456-62. PMID: 15134289.
- Sweeney P, Gimenez LE, Hernandez CC, Cone RD. Targeting the central melanocortin system for the treatment of metabolic disorders. Nat Rev Endocrinol. 2023;19(9):507-519. PMID: 37365323. DOI
- Edinoff AN, Sanders NM, Lewis KB, et al. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurol Int. 2022;14(1):75-88. PMID: 35076581. DOI
- Pettigrew JA, Novick AM. Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. J Midwifery Womens Health. 2021;66(6):740-748. PMID: 34510696. DOI
(Citations retrieved from PubMed — https://pubmed.ncbi.nlm.nih.gov)
Disclaimer: All products sold by CertaPeptides are intended for laboratory research use only. Not for human or veterinary use. Not for consumption. Nothing in this article is medical advice, and no statements should be interpreted as claims to diagnose, treat, cure, or prevent any disease. The FDA-approved use of bremelanotide (Vyleesi) is discussed here solely for research-context reference and does not constitute a recommendation or endorsement of any specific therapeutic use. Researchers using PT-141 in their experiments are responsible for ensuring compliance with all applicable laws, institutional review requirements, and laboratory safety standards.